comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 16:49:21 - browse：141

1:43Traders work on the floor of the New York Stock Exchange on July 12, 2023 in New York City.Spencer Platt/Getty Images

As long-standing recession alarms continue to blare from some forecasters, investors don’t appear to hear them.

The S&P 500 this year, when excluding the ten largest companies, stands at single-digit gains.

Looking ahead, Agati and Moya said they expect the stock market to decline over the remainder of the year, ending 2023 with positive but modest returns. The full economic cooling-off effects of central bank rate hikes have yet to take hold, they said, adding that inflation may not return to normal levels as soon as investors hope.

"The rally will stall out here," Moya said.

MORE: US economy 'quite resilient,' Fed Chair Jerome Powell says

Stoltzfus, however, said there's a "good chance" the stock market will end the year higher than it currently stands.

"We have maintained a fairly bullish posture," he said. "Where the market is trading right now would suggest to us that it has further to go this year."

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

hotspot

WSS

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Printout prescription drug information shouldn’t go digital

STAT Readout Newsletter: Biotech news today

Results on Novartis prostate cancer therapy could expand its use

Roche acquires Telavant from Roivant, adding experimental IBD treatment

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

hotspot

comprehensive

MORE: US economy 'quite resilient,' Fed Chair Jerome Powell says

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Head of FDA's diagnostics center, who led through Covid, retires

At least 13 dead in Texas as scorching temps continue

Roche drug slashes death risk in early

How to save PrEP access — and even expand it

FDA sets aggressive timeline for overhauling inspection procedures

Cancer drug shortages should be causing more outrage

Roivant's CEO is a star, but biotech's black hole persists

At least 13 dead in Texas as scorching temps continue

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Wikipedia

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Future doctors need a strong humanities education

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Cassava Sciences’ Alzheimer’s clinical trials should be halted

CZI to create biohub to build anti

Printout prescription drug information shouldn’t go digital

hotspot

knowledge

hotspot

focus